|
|
Office Locations:
|
Genentech, Inc. 1 DNA Way
South San Francisco, CA 94080
Phone: 650-225-1000
| |
|
|
|
|
|
|
Information Technology
Life Sciences & Healthcare
|
|
|
|
The Roche Venture Fund is the corporate venture fund of the healthcare company Roche. The fund invests in innovative biotech and diagnostics companies to develop commercially successful life science companies. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. RVF invests globally with a portfolio of over 30 companies in 10 countries. Initial investment ranges from CHF 3-10 million, depending on the stage of the company, the pre-money valuation, and the amount being raised. In general, RVP prefers to be in the 15% ownership range. Areas of particular interest to the fund include: oncology, central nervous system, inflammation, virology, in vitro diagnostics, and molecular diagnostics. To date, Roche has had over 20 exits on the public markets and 12 of our portfolio companies have been acquired.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
